Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Castle Biosciences Inc
(NQ:
CSTL
)
31.47
+0.94 (+3.08%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Castle Biosciences Inc
< Previous
1
2
3
4
5
6
7
8
Next >
Castle Biosciences to Host Ribbon Cutting Ceremony at New Corporate Headquarters
May 24, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Supports the American Skin Association with Research Grant
May 21, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Expert Panel Provides Framework for Incorporating DecisionDx-SCC Results Into Clinical Decision Making for Cutaneous Squamous Cell Carcinoma Patients With One or More Risk Factors
May 20, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences to Participate in the Oppenheimer MedTech, Tools, & Diagnostics Summit
May 19, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Tiffany Olson, Seasoned Diagnostics Executive, Joins Castle Biosciences’ Board of Directors
May 11, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Announces First Quarter 2021 Results
May 10, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Announces Pipeline Initiative to Develop Genomic Test Targeting Systemic Therapy Response in Patients with Psoriasis, Atopic Dermatitis and Related Conditions
May 10, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Recognized for Skin Cancer Diagnostics Innovation in 2021 MedTech Breakthrough Awards Program
May 06, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
New Data Demonstrate that 99% of Surveyed Patients Diagnosed With Uveal Melanoma Gain Value From DecisionDx-UM Test
May 05, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Collaborates With the Colorado Melanoma Foundation and Epiphany Dermatology to Provide Free Skin Cancer Screenings Across the Southwest U.S.
May 04, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Supports American Academy of Dermatology's "Skin Cancer, Take a Hike!™" Steps Challenge for Skin Cancer Awareness Month
April 30, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Signs Definitive Agreement to Acquire Myriad myPath® Laboratory
April 27, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences to Release First Quarter 2021 Financial Results, Provide Pipeline Update and Host Conference Call on Monday, May 10, 2021
April 26, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Presents Data Demonstrating DecisionDx-Melanoma as Significant, Independent Predictor of Recurrence in Stage I Cutaneous Melanoma Population
April 23, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Presents Data at the Dermatology Nurses’ Association 2021 Annual Convention
April 22, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Presents Data at the 10th World Congress of Melanoma and 17th European Association of Dermato-Oncology Congress
April 16, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Late-Breaking New Independent Validation Study of 1,674 Patients Demonstrates Castle Biosciences' i31-GEP Artificial Intelligence Algorithm Improves Precision of Sentinel Lymph Node Positivity Prediction in Cutaneous Melanoma
April 15, 2021
From
Castle Biosciences
Via
Business Wire
Largest, Independent, Prospective Study Demonstrates Utility of DecisionDx®-Melanoma for Prediction of Outcomes in Patients With Cutaneous Melanoma Referred for Sentinel Node Biopsy
April 14, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Announces Prospective, Multi-Center Publication Demonstrating DecisionDx®-Melanoma as Significant, Independent Predictor of Patient Outcomes in Cutaneous Melanoma
April 13, 2021
From
Castle Biosciences, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.